U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287748) titled 'A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer' on Nov. 20.
Brief Summary: To evaluate the safety and tolerability of a single intravenous dose of af-001 in patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) refractory to or intolerant of standard-of-care therapy, who have received total thyroidectomy, and to determine the MTD (Maximum tolerated dose)
To evaluate the efficacy and safety of three intravenous doses of af-001 administered at 8-week intervals to patients with radically unresectable, recurrent, metastatic diffe...